385 related articles for article (PubMed ID: 26711747)
1. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Lawitz EJ; O'Riordan WD; Asatryan A; Freilich BL; Box TD; Overcash JS; Lovell S; Ng TI; Liu W; Campbell A; Lin CW; Yao B; Kort J
Antimicrob Agents Chemother; 2015 Dec; 60(3):1546-55. PubMed ID: 26711747
[TBL] [Abstract][Full Text] [Related]
2. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
[TBL] [Abstract][Full Text] [Related]
3. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
[TBL] [Abstract][Full Text] [Related]
4. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
[TBL] [Abstract][Full Text] [Related]
5. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
[TBL] [Abstract][Full Text] [Related]
6. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
Feld JJ; Cypel M; Kumar D; Dahari H; Pinto Ribeiro RV; Marks N; Kamkar N; Bahinskaya I; Onofrio FQ; Zahoor MA; Cerrochi O; Tinckam K; Kim SJ; Schiff J; Reichman TW; McDonald M; Alba C; Waddell TK; Sapisochin G; Selzner M; Keshavjee S; Janssen HLA; Hansen BE; Singer LG; Humar A
Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):649-657. PubMed ID: 32389183
[TBL] [Abstract][Full Text] [Related]
7. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Lok AS; Sulkowski MS; Kort JJ; Willner I; Reddy KR; Shiffman ML; Hassan MA; Pearlman BL; Hinestrosa F; Jacobson IM; Morelli G; Peter JA; Vainorius M; Michael LC; Fried MW; Wang GP; Lu W; Larsen L; Nelson DR
Gastroenterology; 2019 Dec; 157(6):1506-1517.e1. PubMed ID: 31401140
[TBL] [Abstract][Full Text] [Related]
9. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
Hubbard H; Lawitz E
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):9-17. PubMed ID: 29187007
[TBL] [Abstract][Full Text] [Related]
10. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
Zhang Y; Cao Y; Zhang R; Zhang X; Lu H; Wu C; Huo N; Xu X
PLoS One; 2016; 11(11):e0165658. PubMed ID: 27812165
[TBL] [Abstract][Full Text] [Related]
11. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
Gane E; Lawitz E; Pugatch D; Papatheodoridis G; Bräu N; Brown A; Pol S; Leroy V; Persico M; Moreno C; Colombo M; Yoshida EM; Nelson DR; Collins C; Lei Y; Kosloski M; Mensa FJ
N Engl J Med; 2017 Oct; 377(15):1448-1455. PubMed ID: 29020583
[TBL] [Abstract][Full Text] [Related]
12. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
[TBL] [Abstract][Full Text] [Related]
13. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
Osawa M; Imamura M; Teraoka Y; Uchida T; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Chayama K;
J Gastroenterol; 2019 Mar; 54(3):291-296. PubMed ID: 30334096
[TBL] [Abstract][Full Text] [Related]
14. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.
Poordad F; Landis CS; Asatryan A; Jackson DF; Ng TI; Fu B; Lin CW; Yao B; Kort J
Liver Int; 2016 Aug; 36(8):1125-32. PubMed ID: 26778412
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
Kumada H; Watanabe T; Suzuki F; Ikeda K; Sato K; Toyoda H; Atsukawa M; Ido A; Takaki A; Enomoto N; Kato K; Alves K; Burroughs M; Redman R; Pugatch D; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Chayama K
J Gastroenterol; 2018 Apr; 53(4):566-575. PubMed ID: 29052790
[TBL] [Abstract][Full Text] [Related]
17. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis.
Wang X; Fan X; Deng H; Zhang X; Zhang K; Li N; Han Q; Lv Y; Liu Z
Int J Antimicrob Agents; 2019 Dec; 54(6):780-789. PubMed ID: 31284039
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.
Vince B; Hill JM; Lawitz EJ; O'Riordan W; Webster LR; Gruener DM; Mofsen RS; Murillo A; Donovan E; Chen J; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Zhou XJ
J Hepatol; 2014 May; 60(5):920-7. PubMed ID: 24434503
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]